In recent years, immunotherapy, especially immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and its ligand PD-L1, has revolutionized cancer treatment and substantially improved patient outcomes in NSCLC (Suresh et al., 2018). Here, PDCD1 is linked to cancer.